The biologic behavior of squamous cervical carcinoma after neoadjuvant therapy NAT hpv cervical cancer progression to immunohistochemical expression of E-cadherin and CD44v6 Mihaela Madalina Gavrilescu, Raluca Balan, Viorel Scripcariu, Dan Ferariu, Ludmila Lozneanu, Diana Popovici, Cornelia Amalinei Abstract The efficiency of neoadjuvant therapy in cervical carcinoma has been well demonstrated, although the cellular hpv cervical cancer progression of different response to this treatment have not been thoroughly investigated.
- Implicarea genomului papiloma virusului uman (hpv) în oncogeneza cancerului cervical
- Hpv papillomavirus traitement
- Portable Document Format (PDF)
- Anthelmintic drugs are
- Cancer y sarcoma
- Hpv warzen bekampfen
The aim of our study was to assess the correlations between the alterations in E-cadherin and CD44v6 immunoexpression in hpv cervical cancer progression carcinoma, as a tool of evaluation the response to neoadjuvant therapy and its prognostic significance.
The intensity of CD44v6 immunoexpression was higher in more aggressive tumors and E-cadherin immunoexpression was approximately constant among the cases with neoadjuvant therapy.
Involvement of Human Papillomavirus genome in oncogenesis of cervical cancer
Our results demonstrate that the evaluation of CD44v6 immunoexpression in cervical carcinomas is useful for the assessment of tumor response to neoadjuvant therapy and of tumor aggressiveness.
The high level of E-cadherin immunoexpression in tumors with neoadjuvant therapy reflects its involvement in the prevention of HPV oncoproteins action, with benefits on the outcome.
- Wart on face skin cancer
- Cancer testicule has
- Laser wart treatment
- Hpv on uvula treatment
A larger group of patients and a panel of antibodies, including CD4 and COX2, could provide a better characterization of the tumor response to neoadjuvant therapy, with a positive prognosis impact. Int J Cancer ; Hpv cervical cancer progression J Morphol Embryol ; CD44 isoform 6 CD44v6 is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma.
Gynecol Oncol ; 80 1 CD 44 exon v6 as a predictor of lymphatic metastases in cervical carcinoma--an immunocytochemical study of 94 cases. Arch Gynecol Obstet ; 3 Immunohistochemical detection of adhesion molecule CD44 splice variants in lymph node metastases of cervical cancer.
Int J Cancer ; 69 3 CD44 is an independent prognostic factor in early-stage cervical cancer. Int J Cancer ; 74 2 E-cadherin and alpha-catenin expression during tumor progression of cervical carcinoma.
Archive of Clinical Cases
Gynecol Oncol ; Braz Dent J ; 20 1 Anticancer Res ; Altered expression and function of E-cadherin in cervical intraepithelial neoplasia and invasive squamous cell carcinoma. J Pathol ; 2 Complex networks orchestrate epithelial-mesenchymal transitions.
Nat Rev Mol Cell Biol ; Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci ; HPV16 E7 oncogene expression in normal human epithelial cells causes hpv cervical cancer progression changes indicative of an epithelial to mesenchymal transition.
Virology ; 1 Tumor biomarkers in cervical cancer: focus on Ki proliferation factor and E-cadherin expression. Significance of E-cadherin, beta-catenin, and vimentin expression as postoperative prognosis indicators in cervical squamous cell carcinoma.
Hum Pathol ;